The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers
Open accessAbstract
There is a growing appreciation of the potential value of combining novel molecularly-targeted drugs with radiotherapy or chemoradiotherapy. Such approaches have the potential to improve locoregional disease control and cure rates across a diverse range of tumour types. In this report, we outline a rational framework for developing novel drug–radiation combinations. In doing so, we make recommendations regarding the core preclinical data sets that are required to serve as justification for studies in humans and describe potential clinical trial designs that may be adopted by investigators. Radiotherapy (RT) has a pivotal role in the management of many tumours, such that ∼ 50% of cancer patients will receive RT during the course of their illnesses and 40% of those cured of cancer will have received RT as part of their treatment ( http://info.cancerresearchuk.org/ ). Indications for prescribing RT include (i) definitive, curative (radical) treatment; (ii) adjuvant therapy following surgery in an attempt to eradicate microscopic (or rarely macroscopic) residual disease; and (iii) as palliative treatment to ameliorate cancer-related symptoms. In the majority of situations, RT is a highly localised treatment that targets defined volumes of tissue that are known (or suspected) to contain cancer cells. Wide-field hemi-body ( Bashir et al, 2008 ) or total body ( Adkins and DiPersio, 2008 ) irradiation techniques are used rarely in very specific indications, such as metastatic bone disease or ‘conditioning’ before transplantation in haematological malignancies, respectively. In addition, the latest developments in stereotactic body RT (SBRT) techniques have also resulted in protocols that aim to treat oligometastatic disease spread through an organ (or more than one organ) with very precisely delivered RT fields and ablative doses ( Benedict et al, 2010 ). This use of SBRT will certainly expand in the next decade and should be an active area for clinical trials. In recent years, significant improvements have occurred in our technical ability to deliver RT to the target volume (tumour and/or locoregional lymph nodes), while limiting its delivery to critical normal structures. Techniques such as three-dimensional conformal RT, intensity-modulated RT and image-guided RT offer the prospect of significant benefits, both in terms of dose escalation within the tumour and dose sparing in normal organs ( Bhide and Nutting, 2010 ; Staffurth, 2010 ). Clinical studies to test each of these strategies are ongoing in various tumour types; however, the expectation is that gains in tumour control probability may be clinically significant but relatively modest (<10%). In addition, in the near future it is likely that an increasing number of centres will have the capacity to deliver proton and heavy ion therapy. This technology offers highly conformal treatment and may allow clinicians to achieve dose escalation in the tumour while simultaneously sparing normal structures. Systemic cytotoxic chemotherapy is increasingly combined with RT in an attempt to increase tumour control as well as targeting micrometastatic disease outside the radiation fields early in the treatment process ( Bentzen et al, 2007 ). A range of cytotoxic agents has been tested in early trials, but most recent studies have focussed on platins, anti-metabolites (5-FU, gemcitabine) and taxanes. The data set derived from a meta-analysis in squamous cell cancer of the head and neck is particularly strong and definitively shows that the greatest benefit from combining chemotherapy with RT accrues when the agents are administered concomitantly ( Pignon et al, 2000 ). Furthermore, the most clinically active drug is a DNA-damaging agent, cisplatin. These findings suggest that the temporal relationship between the two modalities and the mode of action of the cytotoxic drug are important components of the interaction and have led to cisplatin being used as a ‘radiosensitiser’ in a range of indications. In the case of radical and adjuvant RT, a number of studies have confirmed benefit when systemically administered cytotoxic chemotherapy is combined with RT (chemo-RT) ( Pignon et al, 2000 ; Green et al, 2001 ; Urschel and Vasan, 2003 ; Bernier et al, 2004 , 2005 ; Cooper et al, 2004 ; Lordick and Siewert, 2005 ; Auperin et al, 2006 ; Stupp et al, 2009 ). These studies across a range of tumour types (head and neck, lung, uterine cervical, gastric, oesophageal cancers and glioblastoma multiforme) have shown improved locoregional control, progression-free survival and, in some circumstances, overall survival. There is, as yet, little evidence that this systemic therapy has a strong influence on the rates of distant relapse. It is likely that this trend will continue and chemo-RT may become a standard of care in a wider range of cancers. In the context of palliative RT, there are currently no clinical scenarios in which combined drug and radiation therapy is the standard of care
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“For example, in studies involving drugs that modulate angiogenesis, it is reasonable to hypothesise that vascular normalisation before starting RT may be associated with a better treatment outcome (Jain, 2005).”
BackgroundDNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666
Bese, N. S., Hendry, J., & Jeremic, B. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.03.010 · Cited by 382
Cited by
The Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and Recurrence
Barker, H. E., Paget, J. T. E., Khan, A. A., & Harrington, K. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3958 · Cited by 2,144
Self-citationNuclear physics in particle therapy: a review
Durante, M., & Paganetti, H. (2016) · Reports on Progress in Physics · doi:10.1088/0034-4885/79/9/096702 · Cited by 345
Clinical development of new drug–radiotherapy combinations
on behalf of the NCRI CTRad Academia-Pharma Joint Working Group, Sharma, R. A., Plummer, R., Stock, J. K., Greenhalgh, T. A., Ataman, O., Kelly, S., Clay, R., Adams, R. A., Baird, R. D., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.79 · Cited by 320
Self-citationGong, X., Li, X., Jiang, T., Xie, H., Zhu, Z., Zhou, F., & Zhou, C. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.04.014 · Cited by 303
Metadata
- Authors
- Harrington, K. J., Billingham, L. J., Brunner, T. B., Burnet, N. G., Chan, C. S., Hoskin, P., Mackay, R. I., Maughan, T. S., Macdougall, J., McKenna, W. G., Nutting, C. M., Oliver, A., Plummer, R., Stratford, I. J., Illidge, T., & NCRI Clinical and Translational Radiotherapy Research Working Group
- Venue
- British Journal of Cancer
- Published
- 2011-07-19
- Volume
- 105
- Issue
- 5
- Pages
- 628-639
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2026576427
- Cited by
- 170
- References
- 4
- FWCI
- 6.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.